About Careers Internship MedBlog Contact us
Medindia LOGIN REGISTER
Advertisement

Usefulness of Plasma Levels as a Biomarker for Alzheimer's Disease

by Bidita Debnath on April 20, 2016 at 2:15 AM
Font : A-A+

 Usefulness of Plasma Levels as a Biomarker for Alzheimer's Disease

Amyloid beta (Aβ) peptides are the main component of the amyloid plaques found in Alzheimer patients' brains. A Centre for Healthy Brain Ageing (CHeBA) paper presents the first detailed study of the relationship between plasma levels of two amyloid beta peptides (Aβ1-40 and Aβ1-42), brain volumetrics (measures studying the size of brain, which shrinks with Alzheimer's disease) and cognitive performance in an investigation of the usefulness of plasma levels as a biomarker for Alzheimer's disease (AD).

The study got published in Current Alzheimer Research. Lead author on the paper and head of CHeBA's Proteomics Group at the University of New South Wales, Dr Anne Poljak, said that since amyloid beta (Aβ) peptides are the main component of the amyloid plaques found in Alzheimer patients' brains, changes in levels of Aβ in blood plasma may provide a biomarker for detecting increased risk or early diagnosis of disease.

Advertisement


"While Aβ has traditionally been measured using cerebrospinal fluid, plasma presents a more accessible sample for routine collection and screening although results to date have been variable," Dr Poljak said.

The study examined age-matched cognitively normal controls (n=126), individuals with amnestic mild cognitive impairment (aMCI, n=89) from CHeBA's Sydney Memory & Ageing Study, as well as individuals with Alzheimer's disease (AD, n=39).
Advertisement

Plasma levels of the two peptides and the Aβ1-42/1-40 ratio were lower in aMCI and Alzheimer's disease than in cognitively normal controls, and lower levels of Aβ1-42 were associated with lower global cognition and hippocampal volume and higher levels of white matter hyperintensities (which are believed to contribute to Alzheimer's disease). A genetic component was also identified, with associations between Aβ1-40 and cognitive and brain volume measures predominantly observed in individuals carrying the ε4 allele, while the opposite was observed in non-carriers. Longitudinal analysis revealed greater decline in global cognition and memory for the highest quintiles of Aβ1-42 and the ratio measure.

Director of CHeBA and co-author on the paper, Professor Perminder Sachdev, said he was encouraged by the findings. "These findings certainly suggest that plasma Aβ measures may serve as biomarkers of Alzheimer's disease," he said.

Source: Eurekalert
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
What's New on Medindia
Quiz on Low-Calorie Diet for Diabetes
World Heart Day in 2022- Use Heart for Every Heart
Anemia among Indian Women and Children Remains a Cause of Concern- National Family Health Survey-5
View all
Recommended Reading
News Archive
Date
Category
Advertisement
News Category

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Alzheimers Disease Amyotrophic Lateral Sclerosis (ALS) Genetics of Alzheimer´s disease Mini-Mental Scale (Cognitive Function Test) 

Most Popular on Medindia

Drug Side Effects Calculator Blood Donation - Recipients Find a Hospital Drug Interaction Checker Calculate Ideal Weight for Infants Daily Calorie Requirements Blood - Sugar Chart Sinopril (2mg) (Lacidipine) Indian Medical Journals Sanatogen
This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use
×

Usefulness of Plasma Levels as a Biomarker for Alzheimer's Disease Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests